Top

Published in:

01-06-2021 | Multiple Myeloma | Review Article

Progress in the application of minimal residual disease detection in multiple myeloma

Authors: Xiaojia Zuo, Dingsheng Liu

Published in: Journal of Hematopathology | Issue 2/2021

Abstract

Currently, multiple myeloma is an incurable malignant plasma cell neoplasm, and the incidence rate ranks second in terms of hematological malignancies. Most of the patients are diagnosed at an age between 65 and 74 years, with a median age of 69 years. After the introduction of novel drugs or therapeutic methods, the treatment efficacy became significantly improved in multiple myeloma patients. Minimal residual disease is considered to be the most important reason for relapse in multiple myeloma patients after complete remission, which is significantly related to progression-free survival and overall survival. Therefore, minimal residual disease testing is essential for multiple myeloma patients after treatment. Several high-sensitivity technologies are used to detect minimal residual disease both inside and outside of the bone marrow of multiple myeloma patients after treatment, including cytology technology, molecular biology, and imaging technologies. In recent years, most of these minimal residual disease monitoring assays have made great progress. In this review, we focus on the characteristics and progress of the technologies that have been applied in multiple myeloma patients.

Paiva B, Van Dongen JJ, Orfao A (2015) New criteria for response assessment: Role of minimal residual disease in multiple myeloma. Blood 125(20):3059–3068. https://doi.org/10.1182/blood-2014-11-568907CrossRefPubMedPubMedCentral

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, Van Der Velden VHJ, Perez-Moran JJ, Vidriales MB, Garcia-Sanz R, Jimenez C, Gonzalez M, Martinez-Lopez J, Corral-Mateos A, Grigore GE, Fluxa R, Pontes R, Caetano J, Sedek L, Del Canizo MC, Blade J, Lahuerta JJ, Aguilar C, Barez A, Garcia-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, Van Dongen JJM, Orfao A (2017) Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31(10):2094–2103. https://doi.org/10.1038/leu.2017.29CrossRefPubMedPubMedCentral

Lahuerta JJ, Paiva B, Vidriales MB, Cordon L, Cedena MT, Puig N, Martinez-Lopez J, Rosinol L, Gutierrez NC, Martin-Ramos ML, Oriol A, Teruel AI, Echeveste MA, De Paz R, De Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De La Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF, Group G P C S (2017) Depth of response in multiple myeloma: a pooled analysis of three pethema/gem clinical trials. J Clin Oncol 35(25):2900–2910. https://doi.org/10.1200/JCO.2016.69.2517CrossRefPubMed

Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM (2017) Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 3(1):28–35. https://doi.org/10.1001/jamaoncol.2016.3160CrossRefPubMedPubMedCentral

Rawstron AC, Gregory WM, De Tute RM, Davies FE, Bell SE, Drayson MT, Cook G, Jackson GH, Morgan GJ, Child JA, Owen RG (2015) Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 125(12):1932–1935. https://doi.org/10.1182/blood-2014-07-590166CrossRefPubMedPubMedCentral

Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, Mateos MV, Cibeira MT, Cordon L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, De La Rubia J, Diaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martin A, Hernandez MT, Lahuerta JJ, Blade J, San Miguel JF, Groups P G C S (2012) High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119(3):687–691. https://doi.org/10.1182/blood-2011-07-370460CrossRefPubMed

Takamatsu H, Wee RK, Zaimoku Y, Murata R, Zheng J, Moorhead M, Carlton VEH, Kong KA, Takezako N, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S (2018) A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. Br J Haematol 183(4):664–668. https://doi.org/10.1111/bjh.15002CrossRefPubMed

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, Mccarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6CrossRefPubMed

Thoren KL (2018) Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease. Semin Hematol 55(1):41–43. https://doi.org/10.1053/j.seminhematol.2018.02.008CrossRefPubMed

10.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M-V, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, Van De Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen W-M, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S (2019) International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20(6):e302–e312. https://doi.org/10.1016/s1470-2045(19)30309-2CrossRefPubMed

11.

Caers J, Garderet L, Kortum KM, O’dwyer ME, Van De Donk N, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M (2018) European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 103(11):1772–1784. https://doi.org/10.3324/haematol.2018.189159CrossRefPubMedPubMedCentral

12.

Soh KT, Wallace PK (2019) Monitoring of measurable residual disease in multiple myeloma by multiparametric flow cytometry. Curr Protoc Cytom 90(1). https://doi.org/10.1002/cpcy.63

13.

Flanders A, Stetler-Stevenson M, Landgren O (2013) Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 122(6):1088–1089. https://doi.org/10.1182/blood-2013-05-506170CrossRefPubMedPubMedCentral

14.

Salem D, Stetler-Stevenson M, Yuan C, Landgren O (2016) Myeloma minimal residual disease testing in the united states: evidence of improved standardization. Am J Hematol 91(12):E502–E503. https://doi.org/10.1002/ajh.24540CrossRefPubMedPubMedCentral

15.

Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, Van Dongen J, Rawstron AC (2016) Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom 90(1):26–30. https://doi.org/10.1002/cyto.b.21249CrossRefPubMed

16.

Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, Garcia-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF (2016) Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics Cooperative Study G. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood 127(15):1896–1906. https://doi.org/10.1182/blood-2015-08-665679CrossRefPubMed

17.

Krejcik J, Frerichs KA, Nijhof IS, Van Kessel B, Van Velzen JF, Bloem AC, Broekmans MEC, Zweegman S, Van Meerloo J, Musters RJP, Poddighe PJ, Groen RWJ, Chiu C, Plesner T, Lokhorst HM, Sasser AK, Mutis T, Van De Donk N (2017) Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res 23(24):7498–7511. https://doi.org/10.1158/1078-0432.CCR-17-2027CrossRefPubMedPubMedCentral

18.

Soh KT, Tario JD Jr, Hahn T, Hillengass J, Mccarthy PL, Wallace PK (2020) CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Cytometry B Clin Cytom. https://doi.org/10.1002/cyto.b.21961

19.

Klausz K, Cieker M, Kellner C, Rosner T, Otte A, Krohn S, Lux A, Nimmerjahn F, Valerius T, Gramatzki M, Peipp M (2020) Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy. Haematologica. https://doi.org/10.3324/haematol.2020.251371

20.

Pojero F, Flores-Montero J, Sanoja L, Perez JJ, Puig N, Paiva B, Bottcher S, Van Dongen JJ, Orfao A, Euroflow G (2016) Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry B Clin Cytom 90(1):91–100. https://doi.org/10.1002/cyto.b.21269CrossRefPubMed

21.

Takamatsu H (2017) Comparison of minimal residual disease detection by multiparameter flow cytometry, ASO-qPCR, droplet digital PCR, and deep sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. J Clin Med 6(10). https://doi.org/10.3390/jcm6100091

22.

Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, Crippa C, De Rosa L, Pregno P, Grasso M, Liberati AM, Caravita T, Pisani F, Guglielmelli T, Callea V, Musto P, Cangialosi C, Passera R, Boccadoro M, Palumbo A (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077–2084. https://doi.org/10.1200/JCO.2009.23.7172CrossRefPubMed

23.

Lin J, Su G, Su W, Zhou C (2017) Progress in digital PCR technology and application. Sheng Wu Gong Cheng Xue Bao 33(2):170–177. https://doi.org/10.13345/j.cjb.160269CrossRefPubMed

24.

Pott C, Bruggemann M, Ritgen M, Van Der Velden VHJ, Van Dongen JJM, Kneba M (1956) Mrd detection in B-cell non-Hodgkin lymphomas using ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol 2019:199–228. https://doi.org/10.1007/978-1-4939-9151-8_9CrossRef

25.

Li Q, Huang HJ, Ma J, Wang Y, Cao Z, Karlin-Neumann G, Janku F, Liu Z (2020) Ras/raf mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients. J Cancer 11(12):3543–3550. https://doi.org/10.7150/jca.43729CrossRefPubMedPubMedCentral

26.

Rustad EH, Boyle EM (2020) Monitoring minimal residual disease in the bone marrow using next generation sequencing. Best Pract Res Clin Haematol 33(1):101149. https://doi.org/10.1016/j.beha.2020.101149CrossRefPubMedPubMedCentral

27.

Briney B, Inderbitzin A, Joyce C, Burton DR (2019) Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature 566(7744):393–397. https://doi.org/10.1038/s41586-019-0879-yCrossRefPubMedPubMedCentral

28.

Ho C, Arcila ME (2018) Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions. Semin Hematol 55(1):13–18. https://doi.org/10.1053/j.seminhematol.2018.02.007CrossRefPubMed

29.

Puig N, Conde I, Jimenez C, Sarasquete ME, Balanzategui A, Alcoceba M, Quintero J, Chillon MC, Sebastian E, Corral R, Marin L, Gutierrez NC, Mateos MV, Gonzalez-Diaz M, San-Miguel JF, Garcia-Sanz R (2015) The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Leukemia 29(6):1435–1437. https://doi.org/10.1038/leu.2015.7CrossRefPubMed

30.

Rustad EH, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, Ho C, Kazandjian D, Korde N, Mailankody S, Keats JJ, Akhlaghi T, Viny AD, Mayman DJ, Carroll K, Patel M, Famulare CA, Op Bruinink DH, Hutt K, Jacobsen A, Huang Y, Miller JE, Maura F, Papaemmanuil E, Waage A, Arcila ME, Landgren O (2019) Stability and uniqueness of clonal immunoglobulin CDR3 sequences for mrd tracking in multiple myeloma. Am J Hematol 94(12):1364–1373. https://doi.org/10.1002/ajh.25641CrossRefPubMedPubMedCentral

31.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132(23):2456–2464. https://doi.org/10.1182/blood-2018-06-858613CrossRefPubMedPubMedCentral

32.

Takamatsu H (2020) Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. Int J Hematol 111(4):519–529. https://doi.org/10.1007/s12185-020-02828-7CrossRefPubMed

33.

Pugh TJ (2018) Circulating tumour DNA for detecting minimal residual disease in multiple myeloma. Semin Hematol 55(1):38–40. https://doi.org/10.1053/j.seminhematol.2018.03.002CrossRefPubMed

34.

Oberle A, Brandt A, Voigtlaender M, Thiele B, Radloff J, Schulenkorf A, Alawi M, Akyuz N, Marz M, Ford CT, Krohn-Grimberghe A, Binder M (2017) Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica 102(6):1105–1111. https://doi.org/10.3324/haematol.2016.161414CrossRefPubMedPubMedCentral

35.

Long X, Xu Q, Lou Y, Li C, Gu J, Cai H, Wang D, Xu J, Li T, Zhou X, Xiao M, Wang Y, Mao X, Zhou J, Chen L (2020) The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma. Br J Haematol 189(2):e45–e48. https://doi.org/10.1111/bjh.16440CrossRefPubMed

36.

Mithraprabhu S, Sirdesai S, Chen M, Khong T, Spencer A (2018) Circulating tumour DNA analysis for tumour genome characterisation and monitoring disease burden in extramedullary multiple myeloma. Int J Mol Sci 19(7). https://doi.org/10.3390/ijms19071858

37.

Biancon G, Gimondi S, Vendramin A, Carniti C, Corradini P (2018) Noninvasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: a pilot study. J Mol Diagn 20(6):859–870. https://doi.org/10.1016/j.jmoldx.2018.07.006CrossRefPubMed

38.

Pel J, Choi WWY, Leung A, Shibahara G, Gelinas L, Despotovic M, Ung WL, Marziali A (2018) Duplex proximity sequencing (Pro-Seq): a method to improve DNA sequencing accuracy without the cost of molecular barcoding redundancy. PLoS One 13(10):e0204265. https://doi.org/10.1371/journal.pone.0204265CrossRefPubMedPubMedCentral

39.

Kennedy SR, Schmitt MW, Fox EJ, Kohrn BF, Salk JJ, Ahn EH, Prindle MJ, Kuong KJ, Shen JC, Risques RA, Loeb LA (2014) Detecting ultralow-frequency mutations by duplex sequencing. Nat Protoc 9(11):2586–2606. https://doi.org/10.1038/nprot.2014.170CrossRefPubMedPubMedCentral

40.

Zajec M, Jacobs JFM, Groenen P, De Kat Angelino CM, Stingl C, Luider TM, De Rijke YB, Vanduijn MM (2018) Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies. J Proteome Res 17(3):1326–1333. https://doi.org/10.1021/acs.jproteome.7b00890CrossRefPubMed

41.

Bergen HR 3rd, Dasari S, Dispenzieri A, Mills JR, Ramirez-Alvarado M, Tschumper RC, Jelinek DF, Barnidge DR, Murray DL (2016) Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin Chem 62(1):243–251. https://doi.org/10.1373/clinchem.2015.242651CrossRefPubMed

42.

Barnidge DR, Dasari S, Botz CM, Murray DH, Snyder MR, Katzmann JA, Dispenzieri A, Murray DL (2014) Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res 13(3):1419–1427. https://doi.org/10.1021/pr400985kCrossRefPubMed

43.

Martins CO, Huet S, Yi SS, Ritorto MS, Landgren O, Dogan A, Chapman JR (2020) Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma. J Mol Diagn 22:901–911. https://doi.org/10.1016/j.jmoldx.2020.04.002CrossRefPubMedPubMedCentral

44.

Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, Hultcrantz M, Lu S, Shah U, Hassoun H, Smith E, Lesokhin A, Mailankody S, Landgren O, Thoren K (2020) Comparison of MALDI-Tof mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. Br J Haematol 189(5):904–907. https://doi.org/10.1111/bjh.16443CrossRefPubMedPubMedCentral

45.

Long S, Qin Q, Wang Y, Yang Y, Wang Y, Deng A, Qiao L, Liu B (2019) Nanoporous silica coupled MALDI-Tof ms detection of bence-jones proteins in human urine for diagnosis of multiple myeloma. Talanta 200:288–292. https://doi.org/10.1016/j.talanta.2019.03.067CrossRefPubMed

46.

Mills JR, Barnidge DR, Dispenzieri A, Murray DL (2017) High sensitivity blood-based m-protein detection in sCR patients with multiple myeloma. Blood Cancer J 7(8):e590. https://doi.org/10.1038/bcj.2017.75CrossRefPubMedPubMedCentral

47.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, Da Costa FL, Dimopoulos M-A, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E (2017) Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol 18(4):e206–e217. https://doi.org/10.1016/s1470-2045(17)30189-4CrossRefPubMed

48.

Shah SN, Oldan JD (2017) PET/MR imaging of multiple myeloma. Magn Reson Imaging Clin N Am 25(2):351–365. https://doi.org/10.1016/j.mric.2017.01.003CrossRefPubMed

49.

Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barre L, Michaud AV, Cherel M, Moreau P, Bodet-Milin C, Kraeber-Bodere F (2019) Interest of PET imaging in multiple myeloma. Front Med (Lausanne) 6:69. https://doi.org/10.3389/fmed.2019.00069CrossRef

50.

Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortum KM, Einsele H, Buck AK, Hanscheid H, Samnick S (2019) Comparison of 11C-choline and 11C-methionine PET/CT in multiple myeloma. Clin Nucl Med 44(8):620–624. https://doi.org/10.1097/RLU.0000000000002638CrossRefPubMed

51.

Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, Devaux JY, Mohty M, Talbot JN, Garderet L (2016) 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. Eur J Nucl Med Mol Imaging 43(11):1995–2004. https://doi.org/10.1007/s00259-016-3392-7CrossRefPubMed

52.

Isoda A, Higuchi T, Nakano S, Arisaka Y, Kaira K, Kamio T, Mawatari M, Matsumoto M, Sawamura M, Tsushima Y (2012) 18F-FAMT in patients with multiple myeloma: clinical utility compared to 18F-FDG. Ann Nucl Med 26(10):811–816. https://doi.org/10.1007/s12149-012-0645-9CrossRefPubMed

53.

Caldarella C, Annunziata S, Pagano L, De Stefano V, Rufini V (2017) Improved detection of minimal residual disease by 11C-methionine PET/CT in a young patient with unusual extramedullary presentation of recurrent multiple myeloma. Clin Nucl Med 42(2):e130–e134. https://doi.org/10.1097/RLU.0000000000001462CrossRefPubMed

54.

Sachpekidis C, Hillengass J, Goldschmidt H, Wagner B, Haberkorn U, Kopka K, Dimitrakopoulou-Strauss A (2017) Treatment response evaluation with (18)F-FDG PET/CT and (18)F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl Med Mol Imaging 44(1):50–62. https://doi.org/10.1007/s00259-016-3502-6CrossRefPubMed

55.

Behzadi AH, Raza SI, Carrino JA, Kosmas C, Gholamrezanezhad A, Basques K, Matcuk GR Jr, Patel J, Jadvar H (2018) Applications of PET/CT and PET/MR imaging in primary bone malignancies. PET Clin 13(4):623–634. https://doi.org/10.1016/j.cpet.2018.05.012CrossRefPubMedPubMedCentral

56.

Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A (2015) (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med 40(6):e300–e307. https://doi.org/10.1097/RLU.0000000000000773CrossRefPubMed

57.

Sager S, Ergul N, Ciftci H, Cetin G, Guner SI, Cermik TF (2011) The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skelet Radiol 40(7):843–847. https://doi.org/10.1007/s00256-010-1088-9CrossRef

58.

Spinnato P, Bazzocchi A, Brioli A, Nanni C, Zamagni E, Albisinni U, Cavo M, Fanti S, Battista G, Salizzoni E (2012) Contrast enhanced MRI and (18)F-FDG PET/CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol 81(12):4013–4018. https://doi.org/10.1016/j.ejrad.2012.06.028CrossRefPubMed

59.

Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, Van Hemert R, Angtuaco E, Brown T, Bartel T, Mcdonald J, Anaissie E, Van Rhee F, Crowley J, Barlogie B (2013) Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica 98(1):71–78. https://doi.org/10.3324/haematol.2012.066555CrossRefPubMedPubMedCentral

60.

Zamagni E, Tacchetti P, Cavo M (2019) Imaging in multiple myeloma: how? When? Blood 133(7):644–651. https://doi.org/10.1182/blood-2018-08-825356CrossRefPubMed

61.

Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E (2015) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 33(6):657–664. https://doi.org/10.1200/JCO.2014.57.9961CrossRefPubMed

62.

Chen J, Li C, Tian Y, Xiao Q, Deng M, Hu H, Wen B, He Y (2019) Comparison of whole-body DWI and (18)F-FDG PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma. AJR Am J Roentgenol 213(3):514–523. https://doi.org/10.2214/AJR.18.20989CrossRefPubMed

63.

Rasche L, Alapat D, Kumar M, Gershner G, Mcdonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, Van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N (2019) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 33(7):1713–1722. https://doi.org/10.1038/s41375-018-0329-0CrossRefPubMed

64.

Stecco A, Buemi F, Iannessi A, Carriero A, Gallamini A (2018) Current concepts in tumor imaging with whole-body MRI with diffusion imaging (Wb-MRI-DWI) in multiple myeloma and lymphoma. Leuk Lymphoma 59(11):2546–2556. https://doi.org/10.1080/10428194.2018.1434881CrossRefPubMed

65.

Riola-Parada C, Garcia-Canamaque L, Perez-Duenas V, Garcerant-Tafur M, Carreras-Delgado JL (2016) Simultaneous pet/mri vs pet/ct in oncology. A systematic review. Rev Esp Med Nucl Imagen Mol 35(5):306–312. https://doi.org/10.1016/j.remn.2016.06.001CrossRefPubMed

66.

Sachpekidis C, Hillengass J, Goldschmidt H, Mosebach J, Pan L, Schlemmer HP, Haberkorn U, Dimitrakopoulou-Strauss A (2015) Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. Am J Nucl Med Mol Imaging 5(5):469–478PubMedPubMedCentral

67.

Bal S, Weaver A, Cornell RF, Costa LJ (2019) Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. Br J Haematol 186(6):807–819. https://doi.org/10.1111/bjh.16130CrossRefPubMed

Title: Progress in the application of minimal residual disease detection in multiple myeloma
Authors: Xiaojia Zuo
Dingsheng Liu
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Myeloma
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Polymerase Chain Reaction
Published in: Journal of Hematopathology / Issue 2/2021
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-020-00436-2

At a glance: The STEP trials

Springer Medicine

Progress in the application of minimal residual disease detection in multiple myeloma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

EDTA-induced platelet hypogranulation: beware of dysplasia mimic!

Acquired Glanzmann thrombasthenia: a rare disorder

T-lymphoblastic leukemia/lymphoma with interfollicular growth pattern and Castleman-like morphologic features

Utility of hyperchromic cell percentage, flags, and red cell cytograms generated by Advia-120 hematology analyzer as a potential screening tool in hereditary spherocytosis

A multi-centre case series of alectinib-related erythrocyte membrane changes and associated haemolysis

Is there a relationship between the clinicopathological features of classic Hodgkin lymphoma subtypes and an increase in IgG4-positive plasma cells?